Julie Rachline

Matignon Investissement et Gestion SAS (MIG) is an independent management-owned private equity investment firm based in Paris. MIG was established in 1996 through a management buy-out of Acmer from Banque Worms, formerly part of AXA-UAP and acquired by Deutsche Bank AG in 2001. Following the acquisition, Acmer was delisted. MIG manages private equity and venture capital funds, both generalist and sector specific.

Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France.

Kaneka Eurogentec SA distributes reagents, kits and other related products for the biotechnology, pharmaceutical, and diagnostic sectors. It offers a range of services, from basic research in genomics and proteomics, to services associated with the development and manufacture of diagnostic and therapeutic products. The company was founded in 1985 and is headquartered in Seraing, Belgium.

Voluntis SA develops and markets software solutions for the healthcare industry. The firm specializes in patient relationship management software suited for pharmaceutical, medical devices, and health networks applications. It offers patient monitoring and support programs; mobile data collection; medical device development software; training; and consulting services. The company was founded by Romain Marmot, Etienne Vial, and Pierre Leurent in 2001 and is headquartered in Suresnes, France.

Stimulus SAS is a holding company, which provides consulting services for management and health at work. It offers anti-stress tools to companies. The company was founded by Patrick Légeron in 1989 and is headquartered in Paris, France.

Part of HalioDxinvest SAS, HalioDx SASU is a French company that offers a comprehensive suite of biomarker services to deliver integrated and interpreted data, uncovering the critical biomarkers that drive effective decision-making. The company is based in Marseille, France. The company's services include outsourcing assays such as NGS, qPCR, ELISA, IHC, and IVD testing to Veracyte. The company also offers Immunogram, a service that integrates multi-omic data sets into a single per patient view of key biomarker signatures specific to their own TME. Additionally, Veracyte, a unique multiplex tissue imaging and analysis approach, combines multiple technologies to characterize the tumor microenvironment. The company was founded in 2014 by Vincent Fert, who has been the CEO since 2014.